

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-236US

In Re Application Of: **SALMAN et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/510,362	8 April 2002	TBA	26815	TBA	6318

Title:

alpha,omega--DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE alpha1A ADRENOCEPTOR BLOCKERS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
 - the statement specified in 37 CFR 1.97(e);
 - OR**
 - the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-236US

In Re Application: SALMAN et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/510,362	8 April 2002	TBA	26815	TBA	6318

Title:

alpha,omega-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE alpha1A
ADRENOCEPTOR BLOCKERS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- Charge the amount of _____
 Credit any overpayment.
 Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

(Date)

Signature of Person Mailing Correspondence

Signature

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.



Signature

Dated: May 26, 2005

George E. Heibel, Esq.

Reg. No. 42,648

Ranbaxy Inc.

600 College Road East, Suite 2100

Princeton, NJ 08540

Tel.: (609) 720-5334

Fax: (609) 514-9779

CC:

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-236US Serial No.: 10/510,362

Applicants: SALM REDACTED et al.

Filed: 10/5/2004

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,479,954	10/30/1984	Hirose et al.	424	251	
	A2	4,524,206	6/18/1985	New et al.	544	230	
	A3	4,543,355	9/24/1985	Ishizumi et al.	514	253	
	A4	4,567,180	1/28/1986	Hirose et al.	514	253	
	A5	4,598,078	7/1/1986	Ishizumi et al.	514	252	
	A6	4,745,117	5/17/1988	Ishizumi et al.	514	254	
	A7	4,748,240	5/31/1988	Stack et al.	544	47	
	A8	4,797,488	1/10/1989	Stack et al.	544	295	
	A9	4,804,751	2/14/1989	Abou-Gharia	540	575	
	A10	4,824,999	4/25/1989	Stack	562	498	
	A11	4,871,739	10/3/1989	Baldwin et al.	514	254	
	A12	4,892,943	1/9/1990	Abou-Gharia	540	575	
	A13	4,957,913	9/18/1990	Abou-Gharia et al.	514	216	
	A14	5,183,819	2/2/1993	Abou-Gharia et al.	514	255	
	A15	5,330,762	7/19/1994	Ayer et al.	424	473	
	A16	5,420,278	5/30/1995	Cliffe	544	392	
	A17	6,083,950	7/4/2000	Anand et al.	514	252	
	A18	6,090,809	7/18/2000	Anand et al	514	252	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	WO 93/21179	10/28/1993	PCT	C07D	403/06	
	B2	WO 98/37893	9/3/1998	PCT	A61K	31/495	x - Abstract
	B3	WO 00/05206	2/3/2000	PCT	C07D	207/40	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-236US

Serial No.: 10/510,362

Applicants: SALM REDACTED et al.

Filed: 10/5/2004

Group:

B4	WO 02/44151	6/6/2002	PCT	C07D	209/48	
B5	EP 0 748 800	5/9/2001	EPO	C07D	239/54	
B6	IN 496/DEL/95					
B7	IN 500/DEL/95					
B8	IN 96/DEL/96					

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

C1	Heible & Caine, "Etiology of benign prostatic hyperplasia and approaches to its pharmacological management", <i>Federation Proceedings</i> , <u>45</u> (11):2601-2603 (1986)
C2	Lepor & Rigaud, "The Efficacy of Transurethral Resection of the Prostate in Men with Moderate Symptoms of Prostatism", <i>The Journal of Urology</i> , <u>143</u> :533-537 (1990)
C3	Wennberg et al., "Use of Claims Data Systems to Evaluate Health Care Outcomes. Mortality and Reoperation Following Prostatectomy", <i>JAMA</i> , <u>257</u> (7):933-936 (1987)
C4	Gormley et al., "The Effect of Finasteride in Men with Benign Prostatic Hyperplasia", <i>The New England Journal of Medicine</i> , <u>327</u> (17):1185-1191 (1992)
C5	Oesterling, "Benign Prostatic Hyperplasia - Medical and Minimally Invasive Treatment Options", <i>The New England Journal of Medicine</i> , <u>332</u> (2):99-109 (1995)
C6	Harrison et al., "Molecular characterization of α 1- and α 2-adrenoceptors", <i>Trends in Pharmacological Sciences</i> , <u>12</u> :62-67 (1991)
C7	Bruno et al., "Molecular Cloning and Sequencing of a cDNA Encoding a Human α 1A Adrenergic Receptor", <i>Biochemical and Biophysical Research Communications</i> , <u>179</u> (3):1485-1490 (1991)
C8	Forray et al., "The α 1-Adrenergic Receptor that Mediates Smooth Muscle Contraction in Human Prostate Has the Pharmacological Properties of the Cloned Human α 1c Subtype", <i>Molecular Pharmacology</i> , <u>45</u> :703-708 (1994)
C9	Hirasawa et al., "Cloning, functional expression and tissue distribution of human cDNA for the α 1C-adrenergic receptor", <i>Biochemical and Biophysical Research Communications</i> , <u>195</u> (2):902-909 (1993)
C10	Ramarao et al., "Genomic Organization and Expression of the Human α 1B-Adrenergic Receptor", <i>The Journal of Biological Chemistry</i> , <u>267</u> :21936-21945 (1992)
C11	Schwinn et al., "Cloning and Pharmacological Characterization of Human Alpha-1 Adrenergic Receptors: Sequence Corrections and Direct Comparison with Other Species Homologues", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , <u>272</u> (1):134-142 (1995)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-236US	Serial No.: 10/510,362
	Applicants: SALM REDACTED et al.	
	Filed: 10/5/2004	Group:

C12	Weinberg et al., "Cloning, Expression and Characterization of Human α Adrenergic Receptors α 1A, α 1B and α 1C", <i>Biochemical and Biophysical Research Communications</i> , 201(3):1296-1304 (1994)
C13	Hatano et al., "Pharmacological evidence of distinct α 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery", <i>Br. J. Pharmacol.</i> , 113:723-728 (1994)
C14	Marshall et al., "Noradrenaline contractions of human prostate mediated by α 1A- (α 1C-) adrenoceptor subtype", <i>British Journal of Pharmacology</i> , 115:781-786 (1995)
C15	Yamada et al., "Alpha 1-adrenoceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists", <i>Life Sci.</i> , 54(24):1845-1854 (1994)
C16	Cross et al., "Substituted trifluoromethyl phenyl piperazines as anorectic agents", <i>Eur. J. Med. Chem. - Chemic Therapeutica</i> , 12(2):173-176 (1977)
C17	Samant and Kulkarni, "N-(N4-Aryl-N1 piperazinylmethyl)-4-(4'-methoxyphenyl)-piperidine-2,6-diones: CNS Depressants", <i>J. Indian. Chem. Soc.</i> , LV:819-821 (1978)
C18	Samant and Kulkarni, "Synthesis and Pharmacology of N-(N4-Aryl-N1-Piperazinyl-alkyl) Phthalimides: CNS Depressants", <i>J. Indian. Chem. Soc.</i> , LVI:1002-1005 (1979)
C19	van de Waterbeemd and Testa, "Theoretical Conformational Studies of Some Dopamine Antagonistic Benzamide Drugs: 3-Pyrrolidyl- and 4-Piperidyl Derivatives", <i>Journal of Medicinal Chemistry</i> , 26:203-207 (1983)
C20	Michel et al, "Identification of a single α 1-adrenoceptor corresponding to the α 1A-subtype in rat submaxillary gland", <i>Br J. Pharmacol.</i> , 98:883-889 (1989)
C21	U'Prichard et al., "Prazosin: Differential Affinities for Two Populations of α -Noradrenergic Receptor Binding Sites", <i>European Journal of Pharmacology</i> , 50:87-89 (1978)
C22	Cheng & Prusoff, "Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 per cent Inhibition (I50) of an Enzymatic Reaction", <i>Biochemical Pharmacology</i> , 22:3099-3108 (1973)
C23	Brune et al., "Effects of Selective and Nonselective Alpha-1-Adrenoceptor Antagonists on Intraurethral and Arterial Pressures in Intact Conscious Dogs", <i>Pharmacology</i> , 53:356-368 (1996)

EXAMINER	DATE CONSIDERED
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	